Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: A multitarget approach to radiosensitization

Clinical Cancer Research

Volumn 9, Issue 10 I, 2003, Pages 3749-3755

  Russell, Jeffery S ^a   Burgan, William ^a   Oswald, Kelli A ^a   Camphausen, Kevin ^a   Tofilon, Philip J ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Radiation Research Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; PROTEIN; PROTEIN KINASE B; RAF PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL IMMORTALIZATION; CELL KILLING; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; TUMOR CELL CULTURE; TUMOR CELL LINE; X RAY;

BENZOQUINONES; CELL CYCLE; CELL DEATH; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FIBROBLASTS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; LACTAMS, MACROCYCLIC; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; RIFABUTIN; TIME FACTORS;

EID: 0141568014     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Pirollo, K. F., Hao, Z., Rait, A., Ho, C. W., and Chang, E. H. Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells. Biochem. Biophys. Res. Commun., 230: 196-201, 1997.
2. 2 checkpoint abrogator. Cancer Res., 61: 8211-8217, 2001.
3. Russell, J. S., Raju, U., Gumin, G. J., Lang, F. F., Wilson, D. R., Huet, T., and Tofilon, P. J. Inhibition of radiation-induced nuclear factor-κB activation by an anti-Ras single-chain antibody fragment: lack of involvement in radiosensitization. Cancer Res., 62: 2318-2326, 2002.
4. 2/M phase, and protection from apoptosis. Mol. Cell. Biol., 22: 4189-4201, 2002.
5. Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med., 8: S55-S61, 2002.
6. Gupta, A. K., Bakanauskas, V. J., Cerniglia, G. J., Cheng, Y., Bernhard, E. J., Muschel, R. J., and McKenna, W. G. The Ras radiation resistance pathway. Cancer Res., 61: 4278-4282, 2001.
7. Pietras, R. J., Poen, J. C., Gallardo, D., Wongvipat, P. N., Lee, H. J., and Slamon, D. J. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res., 59: 1347-1355, 1999.
8. Neckers, L. Heat shock protein 90 inhibition by 17-allylamino-17-demethoxy-eldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Commentary re: D. B. Solit et al., 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and Her-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res., 8: 986-993, 2002. Clin. Cancer Res., 8: 962-966, 2002.
9. Neckers, L. Heat shock protein 90 inhibition by 17-allylamino-17-demethoxy-eldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Commentary re: D. B. Solit et al., 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and Her-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res., 8: 986-993, 2002. Clin. Cancer Res., 8: 962-966, 2002.
10. Fertil, B., Dertinger, H., Courdi, A., and Malaise, E. P. Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat. Res., 99: 73-84, 1984.
11. O'Brien, M. C., Healy, S. F., Raney, S. R., Hurst, J. M., Avner, B., Hanly, A., Mies, C., Freeman, J. W., Snow, C., Koester, S. K., and Bolton, W. E. Discrimination of late apoptotic/necrotic cells (type III) by flow cytometry in solid tumors. Cytometry, 28: 81-89, 1997.
12. Yang, J., Yang, J. M., Iannone, M., Shih, W. J., Lin, Y., and Hait, W. N. Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin. Cancer Res., 61: 4010-4016, 2001.
13. Schulte, T. W., and Neckers, L. M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol., 42: 273-279, 1998.
14. Hostein, I., Robertson, D., DiStefano, F., Workman, P., and Clarke, P. A. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res., 61: 4003-4009, 2001.
15. Munster, P. N., Basso, A., Solit, D., Norton, L., and Rosen, N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See The Biology Behind: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001. Clin. Cancer Res., 7: 2228-2236, 2001.
16. Munster, P. N., Basso, A., Solit, D., Norton, L., and Rosen, N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See The Biology Behind: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001. Clin. Cancer Res., 7: 2228-2236, 2001.
17. Solit, D. B., Zheng, F. F., Drobnjak, M., Munster, P. N., Higgins, B., Verbel, D., Heller, G., Tong, W., Cordon-Cardo, C., Agus, D. B., Scher, H. I., and Rosen, N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res., 8: 986-993, 2002.
18. Deschavanne, P. J., and Fertil, B. A review of human cell radiosensitivity in vitro. Int. J. Radiat. Oncol. Biol. Phys., 34: 251-266, 1996.
19. Munster, P. N., Marchion, D. C., Basso, A. D., and Rosen, N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res., 62: 3132-3137, 2002.
20. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., Jr., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.
21. Tezuka, M., Watanabe, H., Nakamura, S., Yu, D., Aung, W., Sasaki, T., Shibuya, H., and Miura, M. Antiapoptotic activity is dispensable for insulin-like growth factor I receptor-mediated clonogenic radioresistance after γ-irradiation. Clin. Cancer Res., 7: 3206-3214, 2001.
22. Fossa, A., Lilleby, W., Fossa, S. D. Gaudemack G., Torlakovic, G., and Berner, A. Independent prognostic significance of HER-2 oncoprotein expression in pNO prostate cancer undergoing curative radiotherapy. Int. J. Cancer, 99: 100-105, 2002.
23. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC), 235: 177-182, 1987.
24. Coffer, P. J., Jin, J., and Woodgett, J. R. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem. J., 335: 1-13, 1998.
25. Ling, C. C., and Endlich, B. Radioresistance induced by oncogenic transformation. Radiat. Res., 120: 267-279, 1989.